# Bosutinib For Autosomal Dominant Polycystic Kidney Disease

> **NCT01233869** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 172 (actual)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** Bosutinib
- **DRUG:** Bosutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01233869
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2014-07
- **Final completion:** 2014-08
- **Target enrollment:** 172 (ACTUAL)
- **Last updated:** 2016-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01233869

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01233869, "Bosutinib For Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01233869. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*